An Uptated View on the Approach to Tricuspid Regurgitation

Clara Weksler

doi:10.36660/ijcs.20200325

Abstract

The incidence of tricuspid regurgitation (TR) associated with left valvular disease is significant ranging from 8% to 35% of cases. , This is most common in conjunction with mitral valve disease but association with aortic valve pathology is not uncommon and frequently related to rheumatic valve disease and much rarer in association with degenerative mitral valve disease. In most cases, the tricuspid regurgitation is so called “functional”, in other words, secondary to dilatation of the annulus as a consequence of [...]

Highlights

The incidence of tricuspid regurgitation (TR) associated with left valvular disease is significant ranging from 8% to 35% of cases.[1,2] This is most common in conjunction with mitral valve disease but association with aortic valve pathology is not uncommon and frequently related to rheumatic valve disease and much rarer in association with degenerative mitral valve disease
Current ESC guidelines 2017 suggest that surgery should be considered in patients with mild or moderate secondary TR with annulus > 40mm or 21 mm/m2 undergoing left-side valve surgery (Class IIa indication, level of evidence C).[5]
The American Heart Association /American College of Cardiology (AHA/ACC) guidelines 2014 recommended in patients with pulmonary hypertension (Class IIa indication, level of evidence C).[6]

Summary

Introduction

The incidence of tricuspid regurgitation (TR) associated with left valvular disease is significant ranging from 8% to 35% of cases.[1,2] This is most common in conjunction with mitral valve disease but association with aortic valve pathology is not uncommon and frequently related to rheumatic valve disease and much rarer in association with degenerative mitral valve disease. Current ESC guidelines 2017 suggest that surgery should be considered in patients with mild or moderate secondary TR with annulus > 40mm or 21 mm/m2 undergoing left-side valve surgery (Class IIa indication, level of evidence C).[5] The American Heart Association /American College of Cardiology (AHA/ACC) guidelines 2014 recommended in patients with pulmonary hypertension (Class IIa indication, level of evidence C).[6]

Results

Conclusion